Robust and Highly Efficient Protocol for Differentiation of Human Pluripotent Stem Cells into Mesenchymal Stem Cells.
Karam M., Abdelalim EM.
Laboratory Study, published in Methods Mol Biol (2022) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Methods Mol Biol (2022)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 32894408
- DOI
- 10.1007/7651_2020_318
Abstract (original English)
Mesenchymal stem cells (MSCs) can be isolated from different sources, such as bone marrow, cord blood, and adipose tissue; however, there are variations in MSC capabilities based on their origin, donor age, and culturing method. Recently, human pluripotent stem cells (hPSCs) have been proposed as an alternative renewal source for generating MSCs with large number. Herein, we describe our recently established All-trans retinoic acid (RA)-based approach for generating a scalable number of MSCs from hPSCs. Our protocol generates highly proliferating MSCs that have all MSC characteristics, including fibroblast-like morphology, expression of the key MSC markers, lack of the hematopoietic markers, and ability to differentiate into the three mesodermal lineages. This RA-based method provides a protocol for generating an unlimited number of hPSC-derived MSCs that could be useful for cell therapy, drug screening, and disease modeling applications.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.